Compare
InnovAge Holding Corp. vs U S Physical Therapy Inc vs GeneDx Holdings Corp. vs Omada Health, Inc.
| Latest fiscal year | InnovAge Holding Corp. INNV | U S Physical Therapy Inc USPH | GeneDx Holdings Corp. WGS | Omada Health, Inc. OMDA |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $989.71M | $780.99M | $427.54M | $260.21M |
| Revenue growth (YoY) | +15.9% | +16.3% | +40.0% | +53.2% |
| Gross margin | 23.0% | 19.2% | 69.7% | 65.7% |
| Operating margin | 0.3% | 11.1% | -3.1% | -4.6% |
| Net margin | -0.3% | 5.1% | -4.9% | -4.9% |
| Net income | -$2.54M | $39.58M | -$21.02M | -$12.78M |
| EPS (Diluted) | -$0.02 | $1.42 | -$0.73 | -$0.35 |
| Operating cash flow | $64.71M | $75.06M | $33.28M | $18.25M |
| Free cash flow | $50.41M | $60.99M | $14.26M | $16.93M |
| Cash & equivalents | $97.89M | $35.57M | $105.00M | $222.04M |
| Total assets | $557.39M | $1.20B | $523.71M | $305.41M |
| Total liabilities | $288.62M | $433.81M | $215.53M | $75.73M |
| Shareholders' equity | $235.60M | $476.89M | $308.18M | $229.68M |
| Return on year-end equity | -1.1% | 8.3% | -6.8% | -5.6% |
| Shares outstanding | 136.02M | n/a | 29.25M | 58.43M |
Revenue, most recent five fiscal years
| Fiscal year | InnovAge Holding Corp. | U S Physical Therapy Inc | GeneDx Holdings Corp. | Omada Health, Inc. |
|---|---|---|---|---|
| Latest | $989.71M Ended 2026-06-30 | $780.99M Ended 2025-12-31 | $427.54M Ended 2025-12-31 | $260.21M Ended 2025-12-31 |
| 1 year earlier | $853.70M Ended 2025-06-30 | $671.35M Ended 2024-12-31 | $305.45M Ended 2024-12-31 | $169.80M Ended 2024-12-31 |
| 2 years earlier | $763.86M Ended 2024-06-30 | $604.80M Ended 2023-12-31 | $202.57M Ended 2023-12-31 | $122.78M Ended 2023-12-31 |
| 3 years earlier | $688.09M Ended 2023-06-30 | $553.14M Ended 2022-12-31 | $234.69M Ended 2022-12-31 | n/a |
| 4 years earlier | $698.64M Ended 2022-06-30 | $495.02M Ended 2021-12-31 | $212.19M Ended 2021-12-31 | n/a |